Drug search by name

Xeljanz and Hepatic disorder

Result of checking the interaction of drug Xeljanz and disease Hepatic disorder for safety when used together.

Check result:

Xeljanz <> Hepatic disorder

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of tofacitinib has been associated with an increased incidence of liver enzyme elevation. No dose adjustment of tofacitinib is necessary in patients with mild hepatic impairment. Patients with moderate hepatic impairment have higher levels of the drug; therefore, the recommended dose of tofacitinib is 5 mg once daily for these patients. Tofacitinib has not been studied in patients with severe hepatic impairment, and its use is not recommended in these patients. The safety and efficacy of tofacitinib has not been studied in patients with positive hepatitis B virus or hepatitis C virus serology. Routine monitoring of liver test is recommended, and if drug-induced liver injury is suspected, therapy should be interrupted until this diagnosis has been excluded. Close monitoring is recommended.

Xeljanz

Generic Name: tofacitinib

Brand Name: Xeljanz, Xeljanz XR

Synonyms: n.a.

What is Xeljanz?